The British-Swedish group, ASTRAZENECA, has acquired an initial participation of between 4 and 5% in the US biotechnology company, ABGENIX, for the sum of around $100 million with the possibility of climbing to 19.9%. Both partners will collaborate in research, development and the marketing of antibodies for cancer treatments.